Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program.
about
Structural basis for antagonism and resistance of bicalutamide in prostate cancerCasodex treatment induces hypoxia-related gene expression in the LNCaP prostate cancer progression modelTherapeutic androgen receptor ligands.Effect of small molecules modulating androgen receptor (SARMs) in human prostate cancer modelsHepatotoxicity Induced by Antiandrogens: A Review of the LiteratureProstate cancer (early).Management of complications of prostate cancer treatment.Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration.Estrogenic side effects of androgen deprivation therapy.Surgical stress delays prostate involution in mice.Prostate cancer management: (1) an update on localised diseaseAdjuvant goserelin improves clinical disease-free survival and reduces disease-related mortality in patients with locally advanced or localized prostate cancer.Poly (A) Binding Protein Cytoplasmic 1 Is a Novel Co-Regulator of the Androgen ReceptorRising prostate-specific antigen after primary prostate cancer therapy.Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer.Improving outcomes in early prostate cancer: Part I--adjuvant treatment.Early and delayed castrations confer a similar survival advantage in TRAMP miceCX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: potential role in prostate cancer bone tropismA proposal for the repositioning of prophylactic breast radiotherapy of prostate cancer patients.Endocrine therapy with or without radical prostatectomy for T1b-T3N0M0 prostate cancer.Bicalutamide 150 mg: practical prescribing in patients with early prostate cancer.Apples and oranges. Re: 7.4-year update of the ongoing bicalutamide Early Prostate Cancer (EPC) trial programme.What's New in Prostate Cancer, Benign Prostatic Hyperplasia, and Minimally Invasive Surgery?: Highlights from the XIXth Congress of the European Association of Urology, March 23-27, 2004, Vienna, Austria
P2860
Q24523708-90C3E38B-34F1-4267-8CA2-CB30C4A8405AQ24795055-5CB4F0CF-2F07-4844-9183-F636FAEE70BBQ25257846-6121F343-829A-4388-A981-D5234F058814Q28487784-6A17A315-1F8E-4FB6-85A7-05E318F87B9DQ29543931-213CCBEA-F0C4-4D89-BC38-08A1E5AB54C7Q33448242-80B6C954-55D5-4E95-8387-046AA999B13AQ33978360-7AB4C245-BCA3-4DBC-9037-904114B02227Q34487137-D32696B6-A9E1-44BC-A5F7-CDD88ED4EBC7Q34537714-4DDCF83E-2CAF-4C73-8031-036DF7CEE1C0Q34743239-9AC2CC9B-C9E5-4783-A5D5-564C7D329993Q35040157-28F70FEA-5FE5-46B0-AF62-7CC4ADB43DEDQ35517935-5D108262-6BCD-43D6-926D-22F52B2DEC6CQ35608929-DAC9C528-8D0C-4EC3-9118-CF70B7FEBA40Q35691973-AC1207E1-FF16-4E0A-B0F0-D76921A678A3Q36395149-DB7C7936-CC9C-4503-B4FA-1D24F3EB1047Q36432836-864297AE-F931-46E5-86A7-32E4D41FAF48Q36595214-56FFCF8E-E26E-4BBC-81C2-04A575CEE297Q37074958-88064466-99EB-49BA-8787-EAFC89E759F2Q40002581-219377CD-9F2B-4E2B-B385-F0E5718B527FQ40340176-D7AA6AF8-EB90-4260-9E5F-5B6DE7FDA792Q44803546-3DB243D8-F6D4-4EE2-A5A4-CD5E1E9DBEC2Q45100344-E738CFE4-AF78-4230-AECD-39020CA5CDB2Q46936634-7A7A1147-D936-47DE-92D5-C3D99E9956D5Q57657325-FD3A7F8E-BB2E-4AF9-94C1-86AE5DC7560F
P2860
Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program.
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Bicalutamide as immediate ther ...... early prostate cancer program.
@ast
Bicalutamide as immediate ther ...... early prostate cancer program.
@en
Bicalutamide as immediate ther ...... early prostate cancer program.
@nl
type
label
Bicalutamide as immediate ther ...... early prostate cancer program.
@ast
Bicalutamide as immediate ther ...... early prostate cancer program.
@en
Bicalutamide as immediate ther ...... early prostate cancer program.
@nl
prefLabel
Bicalutamide as immediate ther ...... early prostate cancer program.
@ast
Bicalutamide as immediate ther ...... early prostate cancer program.
@en
Bicalutamide as immediate ther ...... early prostate cancer program.
@nl
P2093
P1476
Bicalutamide as immediate ther ...... early prostate cancer program.
@en
P2093
Bo-Eric Persson
Casodex Early Prostate Cancer Trialist Group
Chris Tyrrell
D M A Wallace
David G McLeod
Donald Gleason
Geert J C M Kolvenbag
Gerald Chodak
Ira Klimberg
James Montie
P304
P356
10.1097/00005392-200208000-00006
P407
P577
2002-08-01T00:00:00Z